Peptide-Based Breast Ca Vaccines Promising in Early Trials

Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

Investigational vaccines to prevent breast cancer recurrence are showing promise in small clinical trials

SAN ANTONIO—Investigational vaccines to prevent breast cancer recurrence are showing promise in small clinical trials, according to reports from the 29th Annual San Antonio Breast Cancer Symposium.

In a plenary presentation (abstract 4), Col. George Peoples, MD, chief of surgical oncology, Brooke Army Medical Center, Fort Sam Houston, Texas, reported preliminary results from a trial of a vaccine derived from the HER2/neu protein. The vaccine consists of the E75 peptide from the extracellular domain of HER2 mixed with GM-CSF. E75 binds to the HLA-A2 molecule, which is found in about half the population, and stimulates CD8 cells. The E75 vaccine is being developed by Apthera Inc., Scottsdale, Arizona, as NeuVax (see image on p. 1).

Previous studies of the E75 vaccine have been conducted in the metastatic setting in very small numbers of patients. In the current trial, which was largely conducted at Walter Reed Army Hospital, the vaccine was evaluated in a population of 186 women with node-positive, HER2-positive breast cancer who had no evidence of disease after multimodality treatment but had a high risk of recurrence. All patients in the active arms had the HLA-A2 allele, while control patients did not. The investigators evaluated multiple doses and schedules of the vaccine, which was given monthly for 6 months. The results represent the observations across all treatment arms combined.

Follow-up at 20 months showed that vaccinated patients had a recurrence rate of 5.7%, compared with 14.1% in the control group (P = .04). The disease-free survival was 92.5% in the vaccinated arm, compared with 77% for the control arm, Dr. Peoples reported. At 24 months, differences persisted in the arms—with an almost 50% decrease in recurrence with vaccination, from a rate of 16% in the controls to 8.3% in the vaccinated patients (P < .07). However, a late recurrence in the treatment arm resulted in a loss of statistical significance, which was explained by Dr. Peoples as owing to the low event rate, where "a single patient can change the results."

The mortality rate was 4.9% in the control arm and 1% in the vaccinated arm, which was statistically similar. Recurrences in the node-negative patients were observed in 5.7% of the control arm vs 2.0% of the vaccinated arm; rates in the node-positive patients were 24% and 14.2%, respectively (no P values; not prespecified endpoints).

With or without preexisting immunity, all vaccinated patients had a rapid immunologic response until month 4, when response diminished and plateaued. It is possible that boosters should be given at this time, Dr. Peoples said. "We think with this vaccine we are boosting natural immunity, amplifying a preexisting response," he said.

There are a number of caveats to this study, he said. While it is the largest breast cancer vaccine trial ever conducted, it is nevertheless an overall small trial with a small number of events, is nonrandomized, and uses nonstandard dosing. Interestingly, the E75 arm contained twice as many ER-negative/PR-negative patients as the control arm, and few patients in the multiple-dosing strategy actually received what is now regarded as optimal dosing. These factors might bias the study against a favorable outcome in the prevention arm, Dr. Peoples said, adding that despite these factors, the results were positive. The findings portend well enough for the vaccine that a phase III study is being designed, Dr. Peoples said. He plans to also evaluate the vaccine in node-negative patients, as well as HER2-negative patients.

In a press conference, Dr. Peoples discussed the development of the E75 vaccine. "This is a very basic vaccine and much less sophisticated than other cancer vaccines that are in development," he said. "Actually, most people felt that a simple vaccine like this could not work—that we would need multiple peptides to make a 'super vaccine.'"

AE37 Vaccine

Dr. Peoples is also involved in other cancer vaccine development. He is particularly encouraged by the li-Key/HER2/neu MHC class II peptide AE37, which was described at the San Antonio meeting (poster 1122) and is entering a phase II trial. AE37, which is being developed by Antigen Express, Inc., Worcester, Massachusetts, is the first peptide vaccine derived from a tumor-associated antigen that elicits a robust immunologic response in cancer patients without the use of an immunoadjuvant, he said.

Compared to E75, Dr. Peoples commented, "AE37 is also safe and effective, and causes an even more dramatic immune system response."

On the Cover

The image on the cover shows T cells from E75-vaccinated patients attacking breast cancer. Image courtesy of Apthera Inc., Scottsdale, Arizona, which is developing the E75 vaccine as NeuVax.

Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Related Content